Clinical Trial Search

Primary: Percentage of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 100.0; 100.0; 100.0; 100.0 percentage of participants

Primary: Number of Incidence of Treatment Related Major Adverse Cardiac Events — 1; 0; 6 Events

Primary: Pharmacokinetics Cmax Day 1 — 10.4; 22.7; 39.5; 45.2 ng/ml

Primary: Safety and Feasibility as Assessed by Number of Participants With Treatment-related Adverse Events — 5; 3; 8; 7 Participants

Primary: Percent (95% CI) of Participants With Grade 3 or Higher Adverse Events (Dose Finding Cohort) — 71.4; 100 percentage of participants

Primary: Aspart Concentration-time Curve From 0 to 12 Hours Area Under the Insulin Aspart Concentration-Time Curve (AUC0-t). — 894.971; 899.163; 904.131 min*ng/ml

Primary: Mass Balance and Total Recovery of [14C]-Radioactivity in Urine: Fraction of [14C]-Radioactivity Excreted in Urine Expressed as Percentage of the Administered Dose Over…

Primary: Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib — 310; 49.2 Hour*nanograms per milliliter (h*ng/mL)

Primary: Number of Participants With Solicited Administration Site Adverse Events (AEs) After Dose 1 — 0; 0; 0; 0 Participants

Primary: Change-from-baseline in QTc Interval — 2.1; 5.1; -0.1; 4.1 ms — p=<0.05

Primary: Number of Participants With Solicited Local Reactions- Post Dose 1 — 30; 30; 29; 30 Participants

Primary: Cohort 1: Area Under the Plasma Concentration-time Curve up to 30 Minutes Post- Dose (AUC[0-30]) — 156.41; 162.11 Hour * Picogram per Milliliter (h*pg/mL)

Primary: Part 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 725.25; 971.67…

Primary: Areas Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUC0-∞) — 2321566.8; 2358855.5 h*ng/mL

Primary: Adverse Events — 3; 5 Participants